Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305835 · ClinicalTrials.gov registry record
Monogenic Kidney Stone - Genetic Testing
A clinical trial of Rare Kidney Stone Diseases, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 6,000
- Enrollment target
- 1
- Study location
NCT03305835: Recruiting study of Rare Kidney Stone Diseases, sponsored by Mayo Clinic.
NCT03305835 is a study of Rare Kidney Stone Diseases that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 6,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305835, a study of Rare Kidney Stone Diseases, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 6,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will attempt to identify the specific gene (coded in the DNA) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. This study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. This information may help develop more effective treatments for monogenic kidney stone diseases.
Primary Outcome
To identify and define the etiology of monogenic diseases causing nephrolithiasis and nephrocalcinosis by the 90 gene mutation possibly for identification.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,000 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2028-02 |
What NCT03305835 shows while recruiting
NCT03305835 is an observational study that tracks outcomes without assigning an intervention. Its 6,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Rare Kidney Stone Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT03305835 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03305835 about?
NCT03305835 is a clinical study titled "Monogenic Kidney Stone - Genetic Testing". This study will attempt to identify the specific gene (coded in the DNA) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. This study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. Th...
What is the current status of trial NCT03305835?
This trial is currently recruiting. The enrollment target is 6,000 participants. The study started on 2017-09-11. Estimated completion is 2028-02.
What conditions does trial NCT03305835 study?
This clinical trial studies the following conditions: Rare Kidney Stone Diseases.
Who is sponsoring clinical trial NCT03305835?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03305835 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
- NCT03127631 · 6,000 participants · NA
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03539705 · 6,000 participants
Food Allergy Registry at a Single Site
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI